Literature DB >> 9398595

Biochemical and Genetic Tests for Inhibitors of Leishmania Pteridine Pathways

.   

Abstract

The study of antifolate-resistant mutants of the protozoan parasite Leishmania has provided useful information about genetic processes such as gene amplification and mutation and knowledge of the unique features of the pteridine metabolic pathway in this primitive eukaryote. The novel bifunctional dihydrofolate reductase-thymidylate synthase (DHFR-TS) is an essential enzyme, yet most DHFR-TS inhibitors show little promise as potential drugs. Leishmania possess a novel alternative pteridine reductase (PTR1) which is relatively insensitive to methotrexate. We have proposed that the ability of PTR1 to serve as a metabolic bypass and thus modulate drug inhibition of DHFR-TS activity may be responsible for the poor efficacy of many antifolates. In this work, we have sought inhibitors of L. major PTR1 from a collection of 74 compounds. The most potent inhibitors were also tested against L. major DHFR-TS and human DHFR and several compounds showing good activity for PTR1 alone, or for all three reductases, were identified. The activity of these compounds was tested against wild-type promastigotes, and those which were potent inhibitors of both PTR1 and DHFR-TS (but not those active against only PTR1) showed good potencies. Growth inhibition tests of L. major mutants, lacking PTR1 or DHFR-TS (ptr1(-) and dhfr-ts- knockouts) or overexpressing PTR1, were used as a "genetic screen" to assess whether these two pteridine reductases were targets in vivo. Remarkably, only one compound showed a methotrexate-like pattern of inhibition. Six compounds showed good inhibition of Leishmania growth regardless of PTR1 or DHFR-TS levels. These findings suggest that Leishmania cells contain multiple targets for a diverse set of antifolates, with one or more significant targets in addition to DHFR-TS and PTR1. This emphasizes the necessity of combined biochemical and genetic screens in efforts to rationally design chemotherapeutic strategies in Leishmania. Copyright 1997 Academic Press. Copyright 1997 Academic Press

Entities:  

Year:  1997        PMID: 9398595

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  9 in total

1.  In silico work flow for scaffold hopping in Leishmania.

Authors:  Barnali Waugh; Ambarnil Ghosh; Dhananjay Bhattacharyya; Nanda Ghoshal; Rahul Banerjee
Journal:  BMC Res Notes       Date:  2014-11-17

2.  High-resolution structures of Trypanosoma brucei pteridine reductase ligand complexes inform on the placement of new molecular entities in the active site of a potential drug target.

Authors:  Alice Dawson; Lindsay B Tulloch; Keri L Barrack; William N Hunter
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-11-16

3.  Design, synthesis and biological evaluation of novel inhibitors of Trypanosoma brucei pteridine reductase 1.

Authors:  Daniel Spinks; Han B Ong; Chidochangu P Mpamhanga; Emma J Shanks; David A Robinson; Iain T Collie; Kevin D Read; Julie A Frearson; Paul G Wyatt; Ruth Brenk; Alan H Fairlamb; Ian H Gilbert
Journal:  ChemMedChem       Date:  2010-12-29       Impact factor: 3.466

4.  Activity of a novel sulfonamide compound 2-nitro-N-(pyridin-2-ylmethyl)benzenesulfonamide against Leishmania donovani.

Authors:  Manas R Dikhit; Bidyut Purkait; Ruby Singh; Bikash Ranjan Sahoo; Ashish Kumar; Rajiv K Kar; Md Yousuf Ansari; Savita Saini; Kumar Abhishek; Ganesh C Sahoo; Sushmita Das; Pradeep Das
Journal:  Drug Des Devel Ther       Date:  2016-05-26       Impact factor: 4.162

Review 5.  Development of Novel Anti-Leishmanials: The Case for Structure-Based Approaches.

Authors:  Mohini Soni; J Venkatesh Pratap
Journal:  Pathogens       Date:  2022-08-22

6.  Structure-based design of pteridine reductase inhibitors targeting African sleeping sickness and the leishmaniases.

Authors:  Lindsay B Tulloch; Viviane P Martini; Jorge Iulek; Judith K Huggan; Jeong Hwan Lee; Colin L Gibson; Terry K Smith; Colin J Suckling; William N Hunter
Journal:  J Med Chem       Date:  2010-01-14       Impact factor: 7.446

7.  One scaffold, three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening.

Authors:  Chidochangu P Mpamhanga; Daniel Spinks; Lindsay B Tulloch; Emma J Shanks; David A Robinson; Iain T Collie; Alan H Fairlamb; Paul G Wyatt; Julie A Frearson; William N Hunter; Ian H Gilbert; Ruth Brenk
Journal:  J Med Chem       Date:  2009-07-23       Impact factor: 7.446

8.  Gene regulation of pteridine reductase 1 in leishmania promastigotes and amastigotes using a full-length antisense construct.

Authors:  F Kheirandish; M Bandehpour; N Davoudi; N Mosaffa; S Dawood; B Kazemi; A Haghighi; A Khamesipour; H Masjedi; M Mohebali; F Mahboudi
Journal:  Iran J Parasitol       Date:  2013-04       Impact factor: 1.012

9.  Evidence of Pyrimethamine and Cycloguanil Analogues as Dual Inhibitors of Trypanosoma brucei Pteridine Reductase and Dihydrofolate Reductase.

Authors:  Giusy Tassone; Giacomo Landi; Pasquale Linciano; Valeria Francesconi; Michele Tonelli; Lorenzo Tagliazucchi; Maria Paola Costi; Stefano Mangani; Cecilia Pozzi
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.